Human Vaccines Market

Human Vaccines Market (Vaccine Type - Conjugate, Recombinant, Inactivated, Combination, and Attenuated; Product - Pneumococcal, Influenza, Hepatitis, HPV, Meningococcal, Rotavirus, Measles, Typhoid, and Combination; Age Group - Pediatrics, Adolescents, Adults, and Geriatrics; Distribution Channel - Hospital Pharmacies and Drugstores) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

  • According to Transparency Market Research’s latest report on the global human vaccine market for the historical period 2017–2018 and forecast period 2019–2027, extremely low risk of serious and fatal side effects, education and awareness through various governmental and non-profit organizations, growing preference for outsourcing of vaccine manufacturing are projected to drive the global human vaccine market during the forecast period
  • According to the report, the global human vaccine market was valued at US$ 37.8 Bn in 2018 and is anticipated to expand at a CAGR of 8.7% from 2019 to 2027

Request a sample to get extensive insights into the Human Vaccines Market

Extremely Low Risk of Serious and Fatal Side Effects: Key Drivers

  • Like other drugs, vaccines are also associated with certain side effects. However, most of the times, side effects from vaccination are mild and moderate such as soreness, swelling, or redness at the site of injection and fever, rash, and achiness.
  • The risk of serious and fatal side effects with vaccination is extremely low. For instance, serious allergic reaction with Anthrax vaccine is less than once for every 100,000 doses. A number of health care organizations including the CDC, the FDA, the American Medical Association (AMA), and the American Academy of Pediatrics (AAP) also recommend that vaccines are safe.
  • Extremely low risk of serious and fatal side effects associated with vaccines drive the market for vaccines during the forecast period.

Education and Awareness through Various Governmental and Non-Profit Organizations Boost Market Growth

  • The vaccine market is also growing due to increasing awareness and education about the benefits associated with vaccination programs. Every year in the U.S., August is celebrated as the National Immunization Awareness Month.
  • During this month, families, friends, and colleagues are reminded to stay up-to-date on vaccine shots. People also share strategies to increase immunization rates among their communities.
  • The National Association of School Nurses, a non-profit specialty nursing organization, along with Sanofi Pasteur is creating awareness to help prevent children and teens from getting infected by meningococcal disease, through a public health initiative ‘Voices of Meningitis’. Increasing awareness among people as a result of the aforementioned initiatives is likely to contribute to market growth during the forecast period from 2019 to 2027

Strict Regulatory Pathway and High Cost Associated With New Vaccine Discovery and Development to Hamper Market

  • Regulatory requirements for developing a new vaccine are quite challenging, and a company engaged in the discovery and development of a new vaccine can take up to 12 years to 15 years to commercialize it.
  • The average cost to discover and develop a new vaccine is estimated to be US$ 1,000 Mn to US$ 2,000 Mn.
  • Therefore, stringent regulatory approval process and high cost associated with new vaccine discovery and development have been identified as major restraints of the market during the forecast period from 2019 to 2027.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Global Human vaccine Market: Competitive Landscape

  • This report profiles major players in the global human vaccine market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global human vaccine market is highly fragmented, with the presence of a number of international as well as regional players
  • Leading players operating in the global human vaccine market are
    • AstraZeneca plc
    • Bavarian Nordic
    • Bharat Biotech
    • CSL Limited, Emergent BioSolutions, Inc.
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck & Co, Inc.
    • Mymetics
    • Novartis AG
    • Pfizer, Inc.
    • Sanofi S.A.
    • Shenzhen Kangtai Biological Products Co., Ltd.
    • Takeda Pharmaceutical Company Limited.
    • among others

Stuck in a neck-to-neck competition with other brands? Request a custom report on Human Vaccines Market

Global Human vaccine Market: Key Developments

Key players in the global human vaccine market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global human vaccine market. A few expansion strategies adopted by players operating in the global human vaccine market are:

  • In September 2016, Mymetics collaborated with the Texas Biomedical Research Institute. The two organizations would work together to develop a HIV vaccine for Mymetics.
  • In May 2016, CSL Limited received the U.S. FDA approval for FLUCELVAX QUADRIVALENT influenza vaccine primarily used for pediatrics

The report on the global human vaccine market discussed individual strategies, followed by company profiles of manufacturers of human vaccine. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global human vaccine market.

Global Human Vaccine Market – Segmentation

Vaccine Type

  • Conjugate
  • Recombinant
  • Inactivated
  • Combination
  • Attenuated
  • Others

Product Type

  • Pneumococcal
  • Influenza
  • Hepatitis
  • HPV
  • Meningococcal
  • Rotavirus
  • Measles and Rubella
  • Typhoid
  • Combination
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Drugstores
  • Others

Age Group

  • Pediatrics
  • Adolescents
  • Adults
  • Geriatrics

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of human vaccine market?

Human vaccine market to reach the valuation of US$ 81,346.4 Mn by 2027

What is the anticipated CAGR of the human vaccine market in the forecast period?

Human vaccine market is anticipated to expand at a CAGR of 8.7% from 2019 to 2027

What are the key driving factors for the growth of the human vaccine market?

Human vaccine market is driven by extremely low risk of serious and fatal side effects associated with vaccines

Who are the key players in the global human vaccine market?

Key players operating in the human vaccines market include Sanofi S. A., Pfizer, Inc., Novartis AG, Mymetics, Merck & Co, Inc., Johnson & Johnson, GlaxoSmithKline Plc., Bharat Biotech, and Bavarian Nordic.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary : Global Human Vaccine Market

    4. Market Overview

        4.1. Introduction

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Human Vaccine Market Analysis and Forecasts, 2018–2030

    5. Key Insights

        5.1. Product Overview

        5.2. Key Industry Developments

        5.3. Emerging Trends in Human Vaccines Market

    6. Global Human Vaccine Market Analysis and Forecasts, By Vaccine

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value  Forecast By Vaccine, 2018–2030

            6.3.1. Conjugate

            6.3.2. Recombinant

            6.3.3. Inactivated

            6.3.4. Combination

            6.3.5. Attenuated

            6.3.6. Others

        6.4. Market Attractiveness By Vaccine

    7. Global Human Vaccine Market Analysis and Forecasts, By Product

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value  Forecast By Product, 2018–2030

            7.3.1. Pneumococcal

            7.3.2. Influenza

            7.3.3. Hepatitis

            7.3.4. HPV

            7.3.5. Meningococcal

            7.3.6. Rotavirus

            7.3.7. Measles and Rubella

            7.3.8. Typhoid

            7.3.9. Combination

            7.3.10. Others

        7.4. Market Attractiveness By Product

    8. Global Human Vaccine Market Analysis and Forecasts, By Distribution Channel

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value  Forecast By Distribution Channel, 2018–2030

            8.3.1. Hospital Pharmacies

            8.3.2. Drugstores

            8.3.3. Others

        8.4. Market Attractiveness By Distribution Channel

    9. Global Human Vaccine Market Analysis and Forecasts, By Age Group

        9.1. Introduction & Definition

        9.2. Key Findings / Developments

        9.3. Market Value  Forecast By Age Group, 2018–2030

            9.3.1. Pediatrics

            9.3.2. Adolescents

            9.3.3. Adults

            9.3.4. Geriatrics

        9.4. Market Attractiveness By Age Group

    10. Global Human Vaccine Market Analysis and Forecasts, By Region

        10.1. Key Findings

        10.2. Market Value  Forecast By Region

            10.2.1. North America

            10.2.2. Europe

            10.2.3. Asia Pacific

            10.2.4. Latin America

            10.2.5. Middle East & Africa

        10.3. Market Attractiveness By Region

    11. North America Human Vaccine Market Analysis and Forecast

        11.1. Introduction

        11.2. Market Value  Forecast By Vaccine, 2018–2030

            11.2.1. Conjugate

            11.2.2. Recombinant

            11.2.3. Inactivated

            11.2.4. Combination

            11.2.5. Attenuated

            11.2.6. Others

        11.3. Market Value  Forecast By Product, 2018–2030

            11.3.1. Pneumococcal

            11.3.2. Influenza

            11.3.3. Hepatitis

            11.3.4. HPV

            11.3.5. Meningococcal

            11.3.6. Rotavirus

            11.3.7. Measles and Rubella

            11.3.8. Typhoid

            11.3.9. Combination

            11.3.10. Others

        11.4. Market Value  Forecast By Distribution Channel, 2018–2030

            11.4.1. Hospital Pharmacies

            11.4.2. Drugstores

            11.4.3. Others

        11.5. Market Value  Forecast By Age Group, 2018–2030

            11.5.1. Pediatrics

            11.5.2. Adolescents

            11.5.3. Adults

            11.5.4. Geriatrics

        11.6. Market Value  Forecast By Country, 2018–2030

            11.6.1. U.S.

            11.6.2. Canada

        11.7. Market Attractiveness Analysis

            11.7.1. By Vaccine

            11.7.2. By Product

            11.7.3. By Distribution Channel

            11.7.4. By Age Group

            11.7.5. By Country

    12. Europe Human Vaccine Market Analysis and Forecast

        12.1. Introduction

        12.2. Market Value  Forecast By Vaccine, 2018–2030

            12.2.1. Conjugate

            12.2.2. Recombinant

            12.2.3. Inactivated

            12.2.4. Combination

            12.2.5. Attenuated

            12.2.6. Others

        12.3. Market Value  Forecast By Product, 2018–2030

            12.3.1. Pneumococcal

            12.3.2. Influenza

            12.3.3. Hepatitis

            12.3.4. HPV

            12.3.5. Meningococcal

            12.3.6. Rotavirus

            12.3.7. Measles and Rubella

            12.3.8. Typhoid

            12.3.9. Combination

            12.3.10. Others

        12.4. Market Value  Forecast By Distribution Channel, 2018–2030

            12.4.1. Hospital Pharmacies

            12.4.2. Drugstores

            12.4.3. Others

        12.5. Market Value  Forecast By Age Group, 2018–2030

            12.5.1. Pediatrics

            12.5.2. Adolescents

            12.5.3. Adults

            12.5.4. Geriatrics

        12.6. Market Value  Forecast By Country, 2018–2030

            12.6.1. Germany

            12.6.2. U.K.

            12.6.3. France

            12.6.4. Spain

            12.6.5. Italy

            12.6.6. Rest of Europe

        12.7. Market Attractiveness Analysis

            12.7.1. By Vaccine

            12.7.2. By Product

            12.7.3. By Distribution Channel

            12.7.4. By Age Group

            12.7.5. By Country

    13. Asia Pacific Human Vaccine Market Analysis and Forecast

        13.1. Introduction

        13.2. Market Value  Forecast By Vaccine, 2018–2030

            13.2.1. Conjugate

            13.2.2. Recombinant

            13.2.3. Inactivated

            13.2.4. Combination

            13.2.5. Attenuated

            13.2.6. Others

        13.3. Market Value  Forecast By Product, 2018–2030

            13.3.1. Pneumococcal

            13.3.2. Influenza

            13.3.3. Hepatitis

            13.3.4. HPV

            13.3.5. Meningococcal

            13.3.6. Rotavirus

            13.3.7. Measles and Rubella

            13.3.8. Typhoid

            13.3.9. Combination

            13.3.10. Others

        13.4. Market Value  Forecast By Distribution Channel, 2018–2030

            13.4.1. Hospital Pharmacies

            13.4.2. Drugstores

            13.4.3. Others

        13.5. Market Value  Forecast By Age Group, 2018–2030

            13.5.1. Pediatrics

            13.5.2. Adolescents

            13.5.3. Adults

            13.5.4. Geriatrics

        13.6. Market Value  Forecast By Country, 2018–2030

            13.6.1. China

            13.6.2. Japan

            13.6.3. India

            13.6.4. Australia & New Zealand

            13.6.5. Rest of Asia Pacific

        13.7. Market Attractiveness Analysis

            13.7.1. By Vaccine

            13.7.2. By Product

            13.7.3. By Distribution Channel

            13.7.4. By Age Group

            13.7.5. By Country

    14. Latin America Human Vaccine Market Analysis and Forecast

        14.1. Introduction

        14.2. Market Value  Forecast By Vaccine, 2018–2030

            14.2.1. Conjugate

            14.2.2. Recombinant

            14.2.3. Inactivated

            14.2.4. Combination

            14.2.5. Attenuated

            14.2.6. Others

        14.3. Market Value  Forecast By Product, 2018–2030

            14.3.1. Pneumococcal

            14.3.2. Influenza

            14.3.3. Hepatitis

            14.3.4. HPV

            14.3.5. Meningococcal

            14.3.6. Rotavirus

            14.3.7. Measles and Rubella

            14.3.8. Typhoid

            14.3.9. Combination

            14.3.10. Others

        14.4. Market Value  Forecast By Distribution Channel, 2018–2030

            14.4.1. Hospital Pharmacies

            14.4.2. Drugstores

            14.4.3. Others

        14.5. Market Value  Forecast By Age Group, 2018–2030

            14.5.1. Pediatrics

            14.5.2. Adolescents

            14.5.3. Adults

            14.5.4. Geriatrics

        14.6. Market Value  Forecast By Country, 2018–2030

            14.6.1. Brazil

            14.6.2. Mexico

            14.6.3. Rest of Latin America

        14.7. Market Attractiveness Analysis

            14.7.1. By Vaccine

            14.7.2. By Product

            14.7.3. By Distribution Channel

            14.7.4. By Age Group

            14.7.5. By Country

    15. Middle East & Africa Human Vaccine Market Analysis and Forecast

        15.1. Introduction

        15.2. Market Value  Forecast By Vaccine, 2018–2030

            15.2.1. Conjugate

            15.2.2. Recombinant

            15.2.3. Inactivated

            15.2.4. Combination

            15.2.5. Attenuated

            15.2.6. Others

        15.3. Market Value  Forecast By Product, 2018–2030

            15.3.1. Pneumococcal

            15.3.2. Influenza

            15.3.3. Hepatitis

            15.3.4. HPV

            15.3.5. Meningococcal

            15.3.6. Rotavirus

            15.3.7. Measles and Rubella

            15.3.8. Typhoid

            15.3.9. Combination

            15.3.10. Others

        15.4. Market Value  Forecast By Distribution Channel, 2018–2030

            15.4.1. Hospital Pharmacies

            15.4.2. Drugstores

            15.4.3. Others

        15.5. Market Value  Forecast By Age Group, 2018–2030

            15.5.1. Pediatrics

            15.5.2. Adolescents

            15.5.3. Adults

            15.5.4. Geriatrics

        15.6. Market Value  Forecast By Country, 2018–2030

            15.6.1. GCC Countries

            15.6.2. South Africa

            15.6.3. Rest of Middle East & Africa

        15.7. Market Attractiveness Analysis

            15.7.1. By Vaccine

            15.7.2. By Product

            15.7.3. By Distribution Channel

            15.7.4. By Age Group

            15.7.5. By Country

    16. Competition Landscape

        16.1. Market Share Analysis By Company (2019)

        16.2. Company Profiles

            16.2.1. AstraZeneca plc

                16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.1.2. Growth Strategies

                16.2.1.3. SWOT Analysis

            16.2.2. Bavarian Nordic

                16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.2.2. Growth Strategies

                16.2.2.3. SWOT Analysis

            16.2.3. Bharat Biotech

                16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.3.2. Growth Strategies

                16.2.3.3. SWOT Analysis

            16.2.4. CSL Limited

                16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.4.2. Growth Strategies

                16.2.4.3. SWOT Analysis

            16.2.5. Emergent BioSolutions, Inc.

                16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.5.2. Growth Strategies

                16.2.5.3. SWOT Analysis

            16.2.6. GlaxoSmithKline plc.

                16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.6.2. Growth Strategies

                16.2.6.3. SWOT Analysis

            16.2.7. Johnson & Johnson

                16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.7.2. Growth Strategies

                16.2.7.3. SWOT Analysis

            16.2.8. Merck & Co, Inc.

                16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.8.2. Growth Strategies

                16.2.8.3. SWOT Analysis

            16.2.9. Mymetics

                16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.9.2. Growth Strategies

                16.2.9.3. SWOT Analysis

            16.2.10. Novartis AG

                16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.10.2. Growth Strategies

                16.2.10.3. SWOT Analysis

            16.2.11. Pfizer, Inc.

                16.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.11.2. Growth Strategies

                16.2.11.3. SWOT Analysis

            16.2.12. Sanofi S.A.

                16.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.12.2. Growth Strategies

                16.2.12.3. SWOT Analysis

            16.2.13. Shenzhen Kangtai Biological Products Co., Ltd.

                16.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.13.2. Growth Strategies

                16.2.13.3. SWOT Analysis

            16.2.14. Takeda Pharmaceutical Company Limited

                16.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.14.2. Growth Strategies

                16.2.14.3. SWOT Analysis

    List of Tables

    Table 01 Global Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019–2027

    Table 02 Global Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019–2027

    Table 03 Global Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027

    Table 04 Global Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019–2027

    Table 05 Global Human Vaccines Market Size (US$ Mn) Forecast, by Region, 2019–2027

    Table 06 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019–2027

    Table 07 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019–2027

    Table 08 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019–2027

    Table 09 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019–2027

    Table 10 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027

    Table 11 North America Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019–2027

    Table 12 North America Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019–2027

    Table 13 North America Human Vaccines Market Size (US$) Forecast, by Vaccine Type, 2019–2027

    Table 14 North America Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019–2027

    Table 15 North America Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027

    Table 16 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019–2027

    Table 17 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019–2027

    Table 18 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019–2027

    Table 19 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019–2027

    Table 20 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027

    Table 21 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019–2027

    Table 22 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019–2027

    Table 23 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019–2027

    Table 24 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019–2027

    Table 25 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027

    Table 26 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019–2027

    Table 27 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019–2027

    Table 28 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019–2027

    Table 29 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019–2027

    Table 30 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027

    List of Figure

    Figure 01 Global Human Vaccines Market Value Share Analysis, by Vaccine Type, 2018 and 2027

    Figure 02 Global Conjugate Market Revenue (US$ Mn), 2017–2027

    Figure 03 Global Recombinant Market Revenue (US$ Mn), 2017–2027

    Figure 04 Global Inactivated Market Revenue (US$ Mn), 2017–2027

    Figure 05 Global Combination Market Revenue (US$ Mn), 2017–2027

    Figure 06 Global Attenuated Market Revenue (US$ Mn), 2017–2027

    Figure 07 Global Others Market Revenue (US$ Mn), 2017–2027

    Figure 08 Human Vaccines Market Attractiveness Analysis, by Vaccine Type, 2018

    Figure 09 Global Human Vaccines Market Value Share Analysis, by Product, 2018 and 2027

    Figure 10 Global Pneumococcal Market Revenue (US$ Mn), 2017–2027

    Figure 11 Global Influenza Market Revenue (US$ Mn), 2017–2027

    Figure 12 Global Hepatitis Market Revenue (US$ Mn), 2017–2027

    Figure 13 Global HPV Market Revenue (US$ Mn), 2017–2027

    Figure 14 Global Meningococcal Market Revenue (US$ Mn), 2017–2027

    Figure 15 Global Rotavirus Market Revenue (US$ Mn), 2017–2027

    Figure 16 Global Measles and Rubella Market Revenue (US$ Mn), 2017–2027

    Figure 17 Global Typhoid Market Revenue (US$ Mn), 2017–2027

    Figure 18 Global Combination Market Revenue (US$ Mn), 2017–2027

    Figure 19 Global Others Market Revenue (US$ Mn), 2017–2027

    Figure 20 Human Vaccines Market Attractiveness Analysis, by Product, 2018

    Figure 21 Global Human Vaccines Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 22 Global Hospital Pharmacies Market Revenue (US$ Mn), 2017–2027

    Figure 23 Global Drugstores Market Revenue (US$ Mn), 2017–2027

    Figure 24 Global others Market Revenue (US$ Mn), 2017–2027

    Figure 25 Human Vaccines Market Attractiveness Analysis, by Distribution Channel, 2018

    Figure 26 Global Human Vaccines Market Value Share Analysis, by Age Group, 2018 and 2027

    Figure 27 Global Pediatrics Market Revenue (US$ Mn), 2017–2027

    Figure 28 Global Adolescents Market Revenue (US$ Mn), 2017–2027

    Figure 29 Global Adults Market Revenue (US$ Mn), 2017–2027

    Figure 30 Global Geriatrics Market Revenue (US$ Mn), 2017–2027

    Figure 31 Human Vaccines Market Attractiveness Analysis, by Age Group, 2018

    Figure 32 North America Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

    Figure 33 Europe Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

    Figure 34 APAC Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

    Figure 35 Latin America Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

    Figure 36 MEA Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

    Figure 37 Global Human Vaccines Market Attractiveness Analysis, by Region

    Figure 38 China Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

    Figure 39 Japan Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

    Figure 40 ASEAN Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

    Figure 41 Rest of APAC Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

    Figure 42 Asia Pacific Human Vaccines Market Attractiveness Analysis, by Country

    Figure 43 Asia Pacific Human Vaccines Market Attractiveness Analysis, by Product

    Figure 44 Asia Pacific Human Vaccines Market Attractiveness Analysis, by Vaccine Type

    Figure 45 Asia Pacific Human Vaccines Market Attractiveness Analysis, by Age Group

    Figure 46 Asia Pacific Human Vaccines Market Attractiveness Analysis, by Distribution Channel

    Figure 47 U.S. Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

    Figure 48 Canada Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

    Figure 49 North America Human Vaccines Market Attractiveness Analysis, by Country

    Figure 50 North America Human Vaccines Market Attractiveness Analysis, by Product

    Figure 51 North America Human Vaccines Market Attractiveness Analysis, by Vaccine Type

    Figure 52 North America Human Vaccines Market Attractiveness Analysis, by Age Group

    Figure 53 North America Human Vaccines Market Attractiveness Analysis, by Distribution Channel

    Figure 54 Germany Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

    Figure 55 France Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

    Figure 56 U.K. Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

    Figure 57 Italy Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

    Figure 58 Spain Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

    Figure 59 Rest of Europe Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

    Figure 60 Europe Human Vaccines Market Attractiveness Analysis, by Country

    Figure 61 Europe Human Vaccines Market Attractiveness Analysis, by Product

    Figure 62 Europe Human Vaccines Market Attractiveness Analysis, by Vaccine Type

    Figure 63 Europe Human Vaccines Market Attractiveness Analysis, by Age Group

    Figure 64 Europe Human Vaccines Market Attractiveness Analysis, by Distribution Channel

    Figure 65 Brazil Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

    Figure 66 Mexico Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

    Figure 67 Rest of LATAM Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

    Figure 68 Latin America Human Vaccines Market Attractiveness Analysis, by Country

    Figure 69 Latin America Human Vaccines Market Attractiveness Analysis, by Product

    Figure 70 Latin America Human Vaccines Market Attractiveness Analysis, by Vaccine Type

    Figure 71 Latin America Human Vaccines Market Attractiveness Analysis, by Age Group

    Figure 72 Latin America Human Vaccines Market Attractiveness Analysis, by Distribution Channel

    Figure 73 GCC Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

    Figure 74 South Africa Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

    Figure 75 Rest of MEA Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027

    Figure 76 MEA Human Vaccines Market Attractiveness Analysis, by Country

    Figure 77 MEA Human Vaccines Market Attractiveness Analysis, by Product

    Figure 78 MEA Human Vaccines Market Attractiveness Analysis, by Vaccine Type

    Figure 79 MEA Human Vaccines Market Attractiveness Analysis, by Age Group

    Figure 80 MEA Human Vaccines Market Attractiveness Analysis, by Distribution Channel

    Figure 81 Human Vaccine Market Share Analysis, by Company (2018)

Copyright © Transparency Market Research, Inc. All Rights reserved